Table 1 Baseline characteristics of the study subjects

Patients, n

69

11

58

–

Age, years

43.7 ± 13.4

43.4 ± 13.5

43.8 ± 13.5

0.923

Sex (male/female)

40/29

10/1

28/30

0.019

Dialysis/Preemptive kidney transplantation

53/16

9/2

44/14

1.000

Living related donor

36 (52.2)

7 (63.6)

29 (50.0)

0.406

Panel reactive activity > 50%

10 (14.5)

0 (0)

10 (17.2)

0.345

Desensitization treatment

13 (18.8)

1 (9.1)

12 (20.7)

0.676

Number of HLA mismatches

2.88 ± 1.84

2.45 ± 1.97

2.97 ± 1.82

0.354

ABO incompatible transplantation

10 (14.5)

1 (9.1)

9 (15.5)

1.000

Induction treatment (ATG/anti-IL-2)

0/68

0/10

0/58

0.159

Mean follow up duration after transplantation (days)

1835 ± 440

1782 ± 542

1845 ± 423

0.663

Time to transplantation from dialysis (days, IQR)

1387 ± 1611

(84–2109)

1514 ± 1477

(219–2516)

1360 ± 1652

(83–2133)

0.568

Acute rejection

32 (46.4)

8 (72.7)

24 (41.4)

0.056

Mean time of recurrence of IgA on allograft (days, IQR)

–

614 ± 443

(390–726)

–

–

Serum creatinine (at time of recurrence, mg/dL)

2.96 ± 1.52

eGFR-time slope (delta eGFR/year)

−3.64 ± 4.88

−4.50 ± 3.99

−3.47 ± 5.04

0.302

HLA-A2

30 (43.5)

6 (54.5)

24 (41.4)

0.514

HLA-B35

12 (17.4)

2 (18.2)

10 (17.2)

1.000

HLA-DR4

40 (58.0)

9 (81.8)

31 (53.4)

0.104

Tacrolimus

66 (95.7)

10 (90.9)

56 (96.6)

0.411

Cyclosporine

7 (10.1)

2 (18.2)

5 (8.6)

0.309

Mycophenolate mofetil

53 (76.8)

7 (63.6)

46 (79.3)

0.265

Trough level of tacrolimus within one year from transplantation

8.30 ± 1.70

8.92 ± 1.38

8.19 ± 1.74

0.218

TNFSF13 (ng/mL)

16.03 ± 12.95

17.75 ± 14.14

15.66 ± 12.79

0.525

Gd-IgA1 (units/ng IgA)

5.77 ± 6.79

3.28 ± 1.43

6.35 ± 7.40

0.208